Drug Interaction Report

Estradiol Transdermal Patch and Tirzepatide: Interaction Details

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Estradiol Transdermal Patch

Alora® Climara® Esclim® Estraderm® FemPatch® Menostar Menostar® Minivelle®
+

Tirzepatide

Mounjaro Zepbound
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Aug 8, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 194 documented Estradiol Transdermal Patch interactions, 151 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Reduced absorption of oral contraceptives

Interaction Deep Dive

Administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) and a single dose of tirzepatide 5 mg, reduced mean Cmax and AUC of ethinyl estradiol, norgestimate, and norelgestromin and delayed Tmax. Advise patients to switch to a non-oral contraceptive method, or add a barrier method of contraception for at least 4 weeks after initiation of tirzepatide and for 4 weeks after each tirzepatide dose escalation. Non-oral hormonal contraceptives are not likely to be affected by tirzepatide12.

Why it happens (mechanism)

Delayed gastric emptying

Literature reports

1 report — tap to read

a) Following the administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) and a single dose of tirzepatide 5 mg, mean Cmax of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%, 66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in Tmax of 2.5 to 4.5 hours also was observed 12.

Common questions

Can I take Estradiol Transdermal Patch and Tirzepatide together?

Reduced absorption of oral contraceptives Always confirm with your pharmacist or prescriber before making any change.

How serious is the Estradiol Transdermal Patch and Tirzepatide interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

From our Q&A

Real reader questions about these medications, each personally answered by our pharmacist:

Questions for your pharmacist

  • Does my dose of Estradiol Transdermal Patch or Tirzepatide need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: MOUNJARO(TM) subcutaneous injection, tirzepatide subcutaneous injection. Lilly USA LLC (per FDA), Indianapolis, IN, 2022. DailyMed
  2. Product Information: ZEPBOUND(TM) subcutaneous injection, tirzepatide subcutaneous injection. Eli Lilly and Company (per FDA), Indianapolis, IN, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.